•
Mirxes Holding Company Ltd, a Singapore – headquartered RNA technology company, has received a filing notice from the China Securities Regulatory Commission (CSRC) regarding its initial public offering (IPO) of 46,620,000 shares in Hong Kong. The company filed its prospectus with the Hong Kong Stock Exchange in November of last…
•
CBC Group’s R-Bridge Healthcare Fund has made a significant investment of USD 40 million in Mirxes Pte Ltd., a Singapore-based company at the forefront of miRNA technology. This funding is poised to propel Mirxes’ swift growth and its global outreach in the realm of cancer early detection and precision medicine.…
•
Canhelp Genomics, a Chinese company specializing in oncology-focused molecular diagnostics, has formed a strategic partnership with Mirxes Singapore. Together, they will utilize their combined technological and operational strengths to offer solid tumor origin identification testing services to medical practitioners and patients in Singapore, Malaysia, Thailand, Indonesia, and the Philippines. Collaboration…
•
Mirxes Holding Company Ltd, a Singapore-based RNA technology company specializing in blood-based miRNA test kit products, has submitted an updated initial public offering (IPO) prospectus to the Hong Kong Stock Exchange. The document reveals the company’s financial performance as of June 2024. During the first half of the year, Mirxes…
•
Mirxes, a Singapore-based company specializing in cancer diagnostics, has refiled a draft prospectus with the Hong Kong Stock Exchange (HKEX) in anticipation of a public listing. The firm is targeting a minimum capital raise of USD 100 million, aiming for a valuation of at least USD 600 million. This follows…
•
Singapore-based RNA technology company, Mirxes Holding Company Ltd, which specializes in blood-based miRNA test kit products, has announced that it has received Breakthrough Device Designation (BDD) from the US FDA. This prestigious award marks the first time it has been given to a gastric cancer in vitro diagnostic (IVD) product…
•
Mirxes Holding Company Ltd, a Singapore-headquartered RNA technology company specializing in blood-based miRNA test kit products, has successfully closed a Series D financing round, raising USD 50 million. The funding round was supported by a consortium of existing and new investors, including Beijing Fupu, in which the Zhejiang Anji Economic…